GlaxoSmithKline (GSK) - one of the world's leading research-based pharmaceutical and healthcare companies - is committed to improving the quality of human life by enabling people to do more, feel better and live longer. GSK operates in Egypt through its 91%-owned subsidiary GlaxoSmithKline Egypt, which employs around 1,500 staff.
In July 2016, GSK announced plans to build a new EGP60mn (USD3.3mn) manufacturing facility in Cairo, as part of GSK's commitment to invest EGP400mn (USD34.1mn) in Egypt by 2017. According to GSK officials, a large portion of the investment will be used to develop existing production units in accordance with the newest manufacturing technologies. Its latest investment in Egypt assures the production of affordable medicine and falls in line with the company's global initiative to improve medicine access in developing nations.